Multiple Sclerosis (MS) Archives - Medical Conferences

Treatment escalation and de-escalation in late-onset MS

Presented By

Prof. Fredrik Piehl, Karolinska University Hospital, Sweden

Conference

EAN 2024

Type

News article

25 July 2024 10:22

How different are late onset and adult onset MS really?

Presented By

Dr Celine Louapre, Sorbonne University, France

Conference

EAN 2024

Type

News article

25 July 2024 10:17

Retinal OCT markers hold promise for early MS diagnosis

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:13

Early intensive treatment enhances long-term clinical outcomes

Presented By

Dr Pietro Iaffaldano, University of Bari, Italy

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:12

χ-separation can assess the effects of tissue destruction in early MS lesions

Presented By

Dr Jannis Müller, University of Basel, Switzerland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:12

Anti-CD40L antibody safe and effective in a phase 2 study

Trial

Phase 2

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:11

High sGFAP levels are associated with disease progression, independent of NfL or relapse activity

Presented By

Dr Pascal Benkert, University Hospital Basel, Switzerland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:11

Oral glycolipid shows promise in the treatment of MS, especially SPMS

Presented By

Dr Tomoko Okamoto, National Center Hospital, Tokyo, Japan

Trial

Phase 2

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Prioritising high efficacy therapies in children with MS

Presented By

Dr Nail Benallegue, Nantes University, France

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

New insights into the contribution of EBV to MS pathogenesis

Presented By

Prof. Thomas Berger, Medical University of Vienna, Austria

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Early initiation of highly active treatment associated with a lower risk of SPMS

Presented By

Dr Christine Lebrun-Frenay, CHU de Nice, France

Trial

SPAM

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Broad rim lesions correlate with a rapidly progressive MS phenotype

Presented By

Dr Jussi Lehto, University of Turku, Finland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Progressive brain tissue loss precedes the onset of clinical MS by years

Presented By

Dr Christina Azevedo, University of Southern California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

COVID-19 infection associated with higher MS relapse rate

Presented By

Mr David Levitz, Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Rate of grey matter brain atrophy accelerates after menopause

Presented By

Dr Alyssa Nylander, University of California, CA, USA

Trial

EPIC

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity

Presented By

Dr Vinicius Schoeps, University of California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients

Presented By

Dr Yi Chao Foong, Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Smouldering inflammation detectable even in the earliest stages of MS

Presented By

Dr Markus Matilainen, University of Turku, Finland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Fenebrutinib shows rapid reduction of new Gd+ T1 lesions

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Trial

Phase 2, FENopta

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Sickness absence rate increases years before clinical onset of MS

Presented By

Dr Ali Manouchehrinia, Karolinska University, Sweden

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Understanding what an MS cure means and what it takes

Presented By

Prof. Stephen Hauser, University of California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Telerehabilitation effective in improving MS symptoms in patients with moderate disability

Presented By

Dr Maria Petracca, Sapienza University of Rome, Italy

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients

Presented By

Prof. Vincent Van Pesch, UCLouvain, Belgium

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Real-world data supports ocrelizumab prior to conception

Presented By

Dr Wei Yeh, Alfred Health and Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:07

Which patients can initially be treated with platform DMT?

Presented By

Dr Ilaria Addazio, University of Florence, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:44

Retinal layer thickness predicts disability accumulation in early RMS

Presented By

Prof. Gabriel Bsteh, Medical University of Vienna, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:38

Withdrawing DMF in early pregnancy does not increase relapse risk in pregnant patients with MS

Presented By

Prof. Doriana Landi, University of Rome Tor Vergata, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:12

Transcriptome data predicts long-term outcomes in untreated PPMS patients

Trial

ORATORIO

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:42

Teriflunomide prevents conversion to MS in patients with RIS

Presented By

Prof. Christine Lebrun-Frenay, Centre Hospitalier Universitaire de Nice, France

Trial

Phase 3, TERIS

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:39

Positive 4-year efficacy and safety data of ocrelizumab in early MS

Trial

Phase 3, ENSEMBLE

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:36

Gold nanocrystals may be effective as adjunctive MS therapy

Presented By

Prof. Michael Barnett, University of Sydney, Australia

Trial

Phase 2, VISIONARY-MS

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:33

Stem cell therapy fails primary endpoint but improves walking in more advanced progressive MS

Trial

Phase 2

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:30

Behavioural intervention increases daily step count in patients with MS

23 May 2023 11:17

MS therapies not associated with an increased risk of pregnancy complications – An interview with Dr Nadine Bast

Expert

Dr Nadine Bast, University Hospital St. Josef, Bochum, Germany

23 May 2023 11:08

Can remyelination of axons cure patients with MS? An interview with Dr Bernard Zalc

Expert

Dr Bernard Zalc, Sorbonne University, Inserm, Paris, France

23 May 2023 11:07

Re-myelination strategies in MS still pose many unanswered questions

Presented By

Prof. Catherine Lubetzki, Sorbonne University, France

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 12:01

MS associated with a broader Epstein-Barr virus specific T-cell receptor repertoire

Presented By

Dr Tilman Schneider-Hohendorf, University of Muenster, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:58

Cognitive rehab and mindfulness reduce cognitive complaints in MS

Presented By

Dr Ilse Nauta, Vrije Universiteit Amsterdam, the Netherlands

Trial

REMIND-MS

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:56

COVID-19 and MS: lessons learned thus far

Presented By

Prof. Céline Louapre, Sorbonne University, France

Trial

COVISEP

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:52

Ocrelizumab and fingolimod increase the risk of COVID-19 and of worse outcomes

Presented By

Dr Nikos Evangelou, Nottingham University Hospital, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:46

Humoral and cellular immune responses after SARS-CoV-2 vaccination

Presented By

Dr Monika Rabenstein, Karolinska Institute, Sweden

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:42

Pregnancy and infant outcomes in women receiving ocrelizumab

Presented By

Prof. Celia Oreja-Guevara, University Hospital San Carlos, Spain

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:29

New safety data of anti-CD20 mAbs around pregnancy

Presented By

Dr Carolin Schwake, Ruhr-University Bochum, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:24

MS activity and pregnancy outcomes after long-term use of natalizumab

Presented By

Prof. Sandra Thiel, Ruhr University Bochum, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:19

Early treatment with DMT effective in paediatric-onset MS

Presented By

Dr Emilio Portaccio, University of Florence, Italy

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:55

Fingolimod in paediatric MS: results of up to 6 years

Presented By

Dr Kumaran Deiva, Paris South University Hospitals, France

Trial

Phase 3, PARADIGMS

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:50

Switching treatment after initial platform injectable DMT: real-world data

Presented By

Dr Aaron Abrams, Cleveland clinic, OH, USA

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:43

Stem cell transplantation not superior to natalizumab in progressive MS

Presented By

Prof. Tomas Kalincik, Royal Melbourne Hospital, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:37

Efficacy of DMTs fades away in secondary progressive MS

Presented By

Dr Luigi Pontieri, The Danish Multiple Sclerosis Registry, Denmark

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:32

Dimethyl fumarate reduces the risk of a first clinical event in RIS

Presented By

Prof. Darin Okuda, University of Texas Southwestern Medical Center, TX, USA

Trial

Phase 4, ARISE

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:14

How and when to make a timely switch to high-efficacy DMT

Presented By

Dr Dalia Rotstein, University of Toronto, Canada

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:08

Study fails to show non-inferiority of rituximab to ocrelizumab

Presented By

Dr Izanne Roos, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:55

Autologous haematopoietic stem cell transplantation versus DMTs

Presented By

Prof. Tomas Kalincik, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:52

A case for including optic nerve lesions in the McDonald criteria

Presented By

Prof. Frederik Barkhof, Vrije Universiteit Amsterdam, the Netherlands

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:49

Cerebrospinal fluid kappa-free light chains for MS diagnosis

Presented By

Dr Harald Hegen, Medical University of Innsbruck, Austria

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:19

Early, non-disabling relapses increase disability accumulation

Presented By

Dr Cyrus Daruwalla, Cambridge University Hospitals, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:13

Physical impairment is present before perceived MS onset

Presented By

Ms Annalaura Lerede, Imperial College London, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:09

Chronic active MS lesions respond poorly to anti-CD20 antibodies

Presented By

Dr Pietro Maggi, Saint-Luc University Hospital, Belgium

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:06

ECTRIMS 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECTRIMS 2022

15 November 2022 00:08

When to start, switch, and stop MS therapy: Real-world evidence counts

Presented By

Prof. Melinda Magyari, Rigshospitalet, Denmark

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:36

Updated EAN-ECTRIMS guideline on pharmacological MS treatment

Presented By

Prof. Maria Pia Amato, University of Florence, Italy

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:31

Gut microbiota composition associated with disability worsening

Presented By

Dr Ayla Pauwels, Vrije Universiteit Brussel, Belgium

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:26

Teriflunomide in children with MS: final results of TERIKIDS

Presented By

Prof. Tanuja Chitnis, Brigham and Women’s Hospital, MA, USA

Trial

Phase 3, TERIKIDS

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:22

Estimating brain age in MS: machine learning versus deep learning

Presented By

Dr Lars Skattebøl, Oslo University Hospital, Norway

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:17

Ofatumumab improves cognitive processing speed

Presented By

Prof. Ralph H.B. Benedict, University at Buffalo, NY, USA

Trial

Phase 3, ASCLEPIOS I/II

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:13

Ublituximab versus teriflunomide in relapsing MS patients

Presented By

Prof. Lawrence Steinman, Stanford University, CA, USA

Trial

Phase 3, ULTIMATE I; ULTIMATE II

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:07

Ketogenic diet may improve disability and quality of life

Presented By

Dr James Nicholas Brenton, University of Virginia Medical Center, VA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:53

Favourable additional safety data for ofatumumab

Presented By

Prof. Stephen Hauser, University of California, CA, USA

Trial

Phase 3, ALITHIOS

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:45

Predicting new T2 lesions using a machine learning algorithm

Presented By

Mr Bastien Caba, Biogen Digital Health, MA, USA

Trial

Phase 3, ADVANCE; ASCEND

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:38

Evobrutinib reduces volume of slowly expanding lesions

Presented By

Prof. Douglas Arnold, McGill University, Canada

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:34

AAN 2022 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

AAN 2022

19 April 2022 22:42

WNT9B-gene variant associated with doubled relapse risk in MS

Presented By

Ms Marijne Vandebergh, KU Leuven, Belgium

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:57

Melatonin associated with improved sleep quality in MS patients

Presented By

Dr Wan-Yu Hsu, University of California San Francisco, CA, USA

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:55

“Expanded Disability Status Scale 0 is not normal”

Presented By

Dr Stephen Krieger, Mount Sinai Hospital, NY, USA

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:51

Personality trait alterations in MS patients

Presented By

Dr Laura Chu, Memorial University of Newfoundland, Canada

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:49

Charcot Award 2021: Progressive MS, a personal perspective

Presented By

Prof. Alan J. Thompson, University College London, UK

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:48

Cortical lesions predict disease progression and disability accumulation

Presented By

Dr Gian Marco Schiavi, University of Verona, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:40

Ocrelizumab shows long-term benefits in primary progressive MS

Presented By

Prof. Jerry S. Wolinsky, University of Texas Health Science Center at Houston, TX, USA

Trial

Phase 3, ORATORIO

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:39

Changes in GABA-receptor binding among cognitively impaired MS patients

Presented By

Prof. Hanneke Hulst, Amsterdam UMC, the Netherlands

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:28

T2 lesions independently predict early conversion to SPMS

Presented By

Dr Laura Lacruz-Ballester, Health Research Institute La Fe, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:26

Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity

Presented By

Dr Emilie Dugast, Centre de Recherche en Transplantation et Immunologie, France

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:23

The importance of MS progression independent of relapses

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:21

Early predictors of disability progression in paediatric-onset MS

Presented By

Dr Sifat Sharmin, University of Melbourne, Australia

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:15

High-sensitive biomarker detection in MS via novel ELISA assay

Presented By

Prof. Maria Cruz Sádaba, Private University San Pablo CEU, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:13

Cortical lesions predict cognitive impairment 20 years after MS diagnosis

Presented By

Mr Stefano Ziccardi, University of Verona, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:06

Applicability of sNfL measurement in clinical practice

Presented By

Prof. Elias Sotirchos, Johns Hopkins University, MD, USA

Trial

MS PATHS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:04

MRI more sensitive for disease activity than relapses in SPMS

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Trial

Phase 3, EXPAND

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:58

ECTRIMS/EAN Clinical Guidelines on MS treatment: an update

Presented By

Prof. Xavier Montalban, Vall d’Hebron University Hospital, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:37

Rituximab most effective initial MS therapy in Swedish real-world study

Presented By

Mr Peter Alping, Karolinska Institutet, Sweden

Trial

Phase 4, COMBAT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:36

Ublituximab meets primary endpoint for relapsing MS

Presented By

Prof. Lawrence Steinman, Stanford University, CA, USA

Trial

Phase 3, ULTIMATE I, ULTIMATE II

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:33

Dynamic scoring system aids decision to switch MS therapies early

Presented By

Dr Camille Sabathé, French Institute of Health and Medical Research, France

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:31

Long-term suppression of MRI disease activity with ocrelizumab

Presented By

Dr Douglas Arnold, McGill University, Canada

Trial

Phase 3, OPERA I/II, ORATORIO

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:30

Stopping DMT: when or if at all?

Presented By

Prof. Ilya Kister (NYU Grossman School of Medicine, NY, USA); Prof. Gavin Giovannoni (Queen Mary University of London, UK)

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:25

The role of astrocyte phenotypes in acute MS lesions

Presented By

Dr Veit Rothhammer, University of Erlangen-Nürnberg, Germany

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:22

Promising results of intrathecal MSC-NTF cells in progressive MS

Presented By

Dr Jeffrey A. Cohen, Cleveland Clinic, OH, USA

Trial

Phase 2, BCT-101, SPRINT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:18

Preliminary data shows positive results of ATA188 for progressive MS

Presented By

Prof. Douglas Arnold, McGill University, Canada

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:16

Evobrutinib reduces relapses and MRI lesion activity

Presented By

Prof. Jens Kuhle (University Hospital Basel, Switzerland); Prof. Douglas Arnold (McGill University, Canada)

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:15

Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial

Presented By

Prof. Peter Calabresi, Johns Hopkins University, MD, USA

Trial

Phase 2, AFFINITY

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:12

Elezanumab did not outperform placebo in progressive and relapsing MS

Presented By

Prof. Bruce Cree, University of California, CA, USA

Trial

Phase 2, RADIUS-R, RADIUS-P

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:10

Ibudilast reduced retinal atrophy in primary progressive MS

Presented By

Dr Henrik Ehrhardt, Johns Hopkins University, MD, USA

Trial

Phase 2, SPRINT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:07

MS patients at risk of hampered immune response after vaccination

Presented By

Prof. Maria Pia Sormani, University of Genoa, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:49

Immunotherapy in MS does not influence COVID-19 severity and mortality

Presented By

Dr Gabriel Bsteh, Medical University of Vienna, Austria

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:45

Anti-CD20 antibodies associated with worse COVID-19 outcomes

Presented By

Dr Steve Simpson-Yap, University of Melbourne, Australia

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:41

ECTRIMS-EAN consensus on vaccination in MS patients

Presented By

Dr Mauricio Farez, Fundacion FLENI, Argentina

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:35

ECTRIMS 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Trial

COMBAT-MS, SAkuraSky, SAkuraStar, ULTIMATE I and II, ORATORIO

Conference

ECTRIMS 2021

1 November 2021 08:32

Typing behaviour to remotely monitor clinical MS status

Presented By

Dr Ka-Hoo Lam, Amsterdam UMC, the Netherlands

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:37

Positive results from ublituximab versus teriflunomide

Trial

Phase 3, ULTIMATE I, ULTIMATE II

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:35

Masitinib for progressive MS: Perspectives from Prof. Patrick Vermersch

Presented By

Prof. Patrick Vermersch, Lille University in France

Trial

AB07002, EXPAND, ORATORIO

Journal

Physician’s Weekly

Conference

MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

15 April 2021 16:34

MS Relapses “Belong to the Past”: Ofatumumab Safety Good

Presented By

Prof. Stephen L. Hauser , University of California, San Francisco (UCSF), USA

Trial

ASCLEPIOS, ALITHIOS

13 April 2021 17:28

MS: EXCHANGE Trial Perspectives from Prof. Amit Bar-Or

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, USA

Trial

EXCHANGE

Journal

Physician’s Weekly

Conference

MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

13 April 2021 15:35

Risk of COVID-19 not increased in MS patients

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:10

Age and EDSS are risk factors for severe COVID-19

Trial

Cohort study, COVISEP

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:09

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:09

Black MS patients have poorer COVID-19 outcomes

Trial

COViMS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:08

Gut bacteria associated with relapse in paediatric-onset MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:08

Predictive value of CSF Aβ and tau proteins in MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:08

Serum NfL as biomarker for suboptimal treatment response

Trial

Cohort study, Swiss MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:07

Interrupting DMT due to pregnancy increases NfL levels

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Predicting autoimmunity in patients treated with alemtuzumab

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Assessing demyelination using myelin water imaging

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Grey matter network measures predict disability and cognition

Trial

Phase 3, ASCEND

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:05

Lesion-specific perfusion levels affect myelin loss and repair

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:05

Management of progressive MS with approved DMT

Presented By

Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Trial

ASCEND, MS-SMART

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:01

Outcomes in patients on alemtuzumab with thyroid adverse events

Trial

CARE-MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:01

Safety and efficacy of dimethyl fumarate: 13 years of follow-up

Trial

ENDORSE, DEFINE, CONFIRM

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:00

Update on estimated PML risk related to fingolimod

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:00

Less thalamic atrophy in patients initiating ocrelizumab earlier

Conference

MS Virtual

Type

Peer-reviewed article

25 November 2020 16:59

No new safety signals in ofatumumab open-label data

Trial

ALITHIOS, ASCLEPIOS I, ASCLEPIOS II, APLIOS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

Long-term safety and efficacy of ozanimod in RMS

Trial

Phase 3, DAYBREAK

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

Low-dose rituximab as effective as high-dose, but safer

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

TERIKIDS trial extension of teriflunomide in paediatric MS

Trial

Phase 3, TERIKIDS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:56

Teriflunomide improves satisfaction versus prior DMT regardless of age

Trial

Phase 4, Teri-PRO

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:55

Safety and efficacy of cladribine, glatiramer acetate, and more

Trial

CLASSIC-MS, OPTIMUM

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:55

Functional potential of gut microbiome in paediatric MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Modulating BTK-dependent inflammatory signalling in microglia

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Therapeutic potential of anti-MOSPD2 monoclonal antibodies

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Masitinib: a first-in-class TKI as treatment of progressive MS

Trial

AB07002

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Gold nanocrystals may improve brain metabolic profile

Trial

REPAIR-MS, REPAIR-PD, VISIONARY-MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:48

Retinoid-X receptor agonist promotes remyelination

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:48

NG-specific biomarkers differentiate NMOSD from MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:46

Gender-based approach to MS therapeutics: a missed opportunity

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:43

Disease activity during pregnancy in a modern MS cohort

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:27

Cardiovascular risk factors may contribute to brain atrophy in MS patients

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:26

Amantadine, modafinil, and methylphenidate for MS-related fatigue

Trial

Phase 3, TRIUMPHANT-MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:23

Imaging to evaluate remyelination and neuroprotection

Presented By

Dr Benedetta Bodini, Sorbonne University, France

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 13:41

MRI-based clustering of MS patients

Presented By

Dr Raffaello Bonacchi, IRCCS San Raffaele, Italy

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 13:29

Serum NfL predicts long-term clinical outcomes in MS

Presented By

Dr Simon Thebault, Ottawa Hospital Research Institute, Canada

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:39

Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS

Principal Investigator

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:30

High NEDA rates after 2 years of ocrelizumab

Presented By

Prof. Patrick Vermersch, University of Lille, France

Trial

Phase 3, CASTING

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:25

Two trials comparing relapsing MS treatments

Presented By

Dr L. Kappos & Dr T. Sprenger

Trial

Phase 3, OPTIMUM, ASCLEPIOS

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:21

Switching from natalizumab to moderate- versus high-efficacy DMT

Presented By

Dr Carrie M. Hersh, Cleveland Clinic Lerner College of Medicine, OH, USA

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:17

Results of compounds in late stages of development

Presented By

Dr B.A.C. Cree, Dr D.S. Reich, Dr E. Jasińska

Trial

Phase 3, EVOLVE-MS-1, SPI2

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:10

Alemtuzumab efficacy and safety data of over 9 years

Presented By

Dr T. Ziemssen, Dr J. Jones, Prof. P. Vermersch

Trial

Phase 3, CARE-MS

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:07

Fampridine treatment results in routine clinical practice

Presented By

Dr Giovanni Castelnovo, Centre Hospitalier Régional Universitaire de Nîmes, France

Trial

LIBERATE

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:05

Air pollution is a possible risk factor for MS

Presented By

Prof. Roberto G.E. Bergamasch, IRCCS Mondino Foundation, Italy

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 11:31

LUTS in the neuro-urologic patient

Presented By

Dr Lysanne Campeau , McGill University, Canada

Conference

EAU 2020

Type

Peer-reviewed article

24 August 2020 11:20

Cognitive assessment in MS

Presented By

Prof. Dawn Langdon, Royal Holloway University of London, United Kingdom

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 23:56

Induction therapy over treatment escalation

Presented By

Prof. Alasdair Coles, Cambridge University Hospitals, United Kingdom

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 23:38

The maternal perspective: when to stop/resume treatment and risks for progression

Presented By

Dr Emilio Portaccio, University of Florence, Italy

Trial

PRIMS

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 23:28

Challenges in diagnosing and treating progressive MS

Presented By

Dr Xavier Montalban, University of Toronto, Canada

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 23:26

Use of clinical registries in phase 4 of DMT

Presented By

Prof. Sandra Vukusic, Lyon University Hospital, France

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 23:15

Treatment escalation over induction therapy

Presented By

Dr Emmanuelle Waubant, University of California, San Francisco, USA

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 22:40

Foetal/child perspective: risks related to drug exposure and breastfeeding

Presented By

Dr Kerstin Hellwig, Ruhr-Universität Bochum, Germany

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 22:29

Risk factors for conversion to secondary progressive MS

Presented By

Dr Pietro Iaffaldano, University of Bari Aldo Moro, Italy

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 22:28

Genes, environment, and safety monitoring in using registries

Presented By

Prof. Tomas Olsson, Karolinska Institute, Sweden

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 22:17

Tool to measure quality of life in MS

Presented By

Dr Deborah Miller, Cleveland Clinic, OH, USA

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 22:08

Influence of age on disease progression

Presented By

Dr Viktor von Wyl, University of Zurich, Switzerland

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 21:43

Patient awareness about family planning represents a major knowledge gap

Presented By

Prof. Marie D’Hooghe, National MS Center, Belgium

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 21:33

Transplantation of autologous mesenchymal stem cells

Presented By

Prof. Dimitrios Karussis, Hebrew University of Jerusalem, Israel

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 21:30

Risk of hypogammaglobulinemia and rituximab

Presented By

Dr Susanna Hallberg, Karolinska Institute, Sweden

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 21:18

Novel ways to assess MS

Presented By

Dr Megan Sokolowski, Prof. Jeremy Hobart

Trial

Phase 3, SPI2

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 21:11

Siponimod delays time to wheelchair

Presented By

Prof. Patrick Vermersch, Lille University, France

Trial

Phase 3, EXPAND

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 20:31

Determinants of outcomes for natalizumab-associated PML

Presented By

Prof. Chris McGuigan, University College Dublin, Ireland

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 20:21

Late-breaking: Role for CSF markers in autoimmune astrocytopathies

Presented By

Dr Iris Kleerekooper, University College London, United Kingdom

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 20:13

Exposure to DMTs reduces disability progression

Presented By

Dr Mattia Fonderico, University of Florence, Italy

Trial

E-MUSIC

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 20:01

Sustained reduction in disability progression with ocrelizumab

Presented By

Prof. Jerry Wolinsky, University of Texas, USA

Trial

Phase 3, ORATORIO

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 19:32

Serum immunoglobulin levels and risk of serious infections

Presented By

Prof. Tobias Derfuss, University Hospital Basel, Switzerland

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 19:23

Predicting long-term sustained disability progression

Presented By

Prof. Tomas Kalincik, University of Melbourne, Australia

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 19:03

Treatment response scoring systems to assess long term prognosis

Presented By

Dr Jordi Río, University Hospital Vall d’Hebron, Barcelona, Spain

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 18:05

Late-breaking: Continuation of natalizumab or interruption during pregnancy

Presented By

Dr Doriana Landi, Tor Vergata University, Italy

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 13:35

EAN guideline on palliative care

Presented By

Dr Alessandra Solari, Carlo Besta Neurological Institute, Italy

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 12:24

Late-breaking: Ofatumumab versus teriflunomide in relapsing MS

Trial

Phase 3, ASCLEPIOS

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 12:08

Late-breaking: Myelin-peptide coupled red blood cells

Presented By

Prof. Andreas Lutterotti, University of Zurich, Switzerland

Trial

Phase 1, ETIMS-red

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 11:34

Targeted therapies for NMOSD in development

Presented By

Dr Dean Wingerchuk, Mayo Clinic, Rochester, United States

Trial

Phase 3, PREVENT

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 11:17

Treating MS from disease onset

Presented By

Dr Kjell-Morten Myhr, Haukeland University Hospital, Norway

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 23:29

Prognostic blood and MRI biomarkers

Trial

EXPAND

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 22:31

Long-term effects of established treatments

Trial

CARE-MS I, CLARITY

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 21:33

Randomised and observational studies comparing treatments

Presented By

Prof. Giancarlo Comi, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, SUNBEAM and RADIANCE

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 20:34

Experimental MS treatments

Trial

MS-SPI; TG1101-RMS201

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 19:36

Generalised EBV vaccine for progressive MS well-tolerated

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 15:37

Autologous haematopoietic stem cell transplantation

Presented By

Dr Alice Mariottini, Careggi University Hospital, Italy

Trial

Phase 3, MIST

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 14:38

Promising results of novel NMOSD treatments

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 09:40

Three very promising new treatments of NMOSD

Presented By

Dr Stacey Clardy & Prof. Bruce Cree

Trial

PREVENT, SAkuraSky

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 23:07

Immune tolerance by peptide-loaded tolerogenic dendritic cells

Expert

Dr Irati Zubizarreta, Institut d’Investigacions Biomediques August Pi Sunyer, Spain

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 22:08

New compounds for MS treatment

Trial

Phase 2, RADIUS-R, RADIUS-D

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 21:10

Sequencing of high-efficacy disease-modifying treatments in MS

Trial

OCTAVE

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 20:12

Biotin, ocrelizumab, and ibudilast in progressive MS

Expert

Dr Andrew Goodman, University of Rochester School of Medicine and Dentistry, USA

Trial

ORATORIO, Phase 3; SPRINT-MS, Phase 2; MS-SPI, Phase 3

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 19:15

No increased MS relapse risk postpartum

Expert

Dr Annette Langer-Gould, Kaiser Permanente Southern California, Pasadena, USA

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 18:16

McDonald Criteria MS often misapplied and misunderstood

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 17:17

Clinical relevance of neurofilament light chain levels

Trial

Phase 3, EXPAND, ADVANCE, CHAMPS, MSCRG, SENTINEL

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 10:19